Opportunity Information: Apply for RFA CA 14 011
Apply for RFA CA 14 011
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Molecular and Cellular Characterization of Screen Detected Lesions Coordinating Center and Data Management Group (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Jun 6, 2014 and posted on Jun 6, 2014.
- Applicants must submit their applications by Sep 17, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: For profit organizations other than small businesses State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign Institutions Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This NIH Funding Opportunity Announcement (RFA-CA-14-011) supports a single Coordinating Center and Data Management Group (CDMG) through a U01 cooperative agreement to serve as the operational backbone of a larger research Consortium focused on cancers found through screening. The overall Consortium goal is to carry out deep molecular and cellular characterization of screen-detected early lesions and to compare them with cancers detected in the interval between screenings and with cancers detected after symptoms appear. By contrasting these groups, the program aims to clarify what makes some early lesions indolent versus aggressive, and to improve the ability to predict which lesions are likely to progress.
The scientific context behind the initiative is the growing recognition that screening can detect abnormalities that may never become clinically dangerous, alongside lesions that are truly early forms of lethal disease. The Consortium is therefore designed to distinguish biological features of lesions detected by screening from those found because they grew quickly (interval cancers) or because they produced symptoms. The work spans tumor tissue, individual cancer and noncancer cells, and key elements of the tumor microenvironment, with an emphasis on approaches that can capture both molecular states and cellular composition. The FOA explicitly encourages enabling technologies and analytical strategies that can define cellular and molecular phenotypes of early lesions, probe whether lesion behavior is predictable or partly stochastic, and ultimately improve predictions about lesion fate over time.
While the Consortium includes multiple independent, multidisciplinary research teams, this specific FOA is not for those site-focused biology projects. It is for the centralized group that coordinates the collaboration and makes the data and biospecimen infrastructure function. The individual research teams in the Consortium are expected to study one or more cancer sites listed in the announcement: breast, prostate, lung, melanoma, and pancreas. Each team is expected to integrate clinical and research expertise, reflecting the clinical realities of screening, diagnosis, pathology review, specimen handling, and patient follow-up. Teams are also expected to share results broadly within the Consortium and to build cross-team projects that use combined methods and expertise rather than operating as isolated labs.
A major shared deliverable across the Consortium is the creation of an annotated biospecimen repository that includes screen-detected lesions and interval cancers, with associated clinical and other metadata needed to interpret molecular findings. The CDMG plays a central role in making that repository usable and scientifically credible by establishing consistent protocols, data standards, and tracking systems. This includes developing and maintaining data management systems, supporting protocol development for the biorepository, and ensuring that specimens and data are annotated in a way that supports cross-study comparisons and integrative analyses.
The CDMG responsibilities are spelled out in three main areas. First, it provides coordination for consortium-wide meetings, conferences, and other collaborative activities, which typically includes scheduling, agenda development, capturing action items, and maintaining regular communication channels among investigators and NIH staff involved in the cooperative agreement. Second, it provides statistical and computational support, meaning the center is expected to help with study design considerations, analysis plans, cross-team harmonization, and integrative computational analyses that allow consortium data to be combined and compared. Third, it leads data management and protocol development for the biorepository, including data dictionaries, quality control processes, governance for data submissions and access within the Consortium, and the practical mechanics required to keep a multi-site repository consistent over time.
Mechanistically, this is a discretionary funding program using a cooperative agreement (U01), which signals substantial NIH involvement in the project’s oversight and coordination compared with a standard research grant. The activity category is listed under education/health, and the participating NIH agency is the National Institutes of Health, with the program aligned to cancer cause and prevention research, cancer detection and diagnosis research, and cancer biology research (CFDA 93.393, 93.394, 93.396).
Funding details indicate one expected award, with an estimated total program funding level of $500,000 and an award ceiling of $300,000. There is no cost sharing or matching requirement. Key dates show the FOA was posted June 6, 2014, with an original and current closing date of September 17, 2014, and an archive date of October 18, 2014, indicating the opportunity is historical rather than currently open.
Eligibility is broad and includes public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (including small businesses and other than small businesses), and state governments, with additional categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and eligible federal agencies. Foreign institutions and other non-U.S. entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible; however, foreign components as defined by NIH policy are allowed, which typically refers to specific project elements conducted abroad under an otherwise eligible applicant organization, subject to NIH rules.
In practical terms, the CDMG award is meant to ensure that the Consortium functions like a unified program rather than a loose federation of projects. By centralizing coordination, analytics support, and data/biorepository infrastructure, NIH is aiming to make the resulting datasets and specimens comparable across tumor types and research teams, accelerate shared discovery, and produce conclusions about screen-detected lesions that are stronger than what isolated studies could generate.
Frequently Asked Questions (FAQs) - NIH RFA-CA-14-011 (Coordinating Center and Data Management Group)
1) What is this funding opportunity (RFA-CA-14-011) designed to support?
This NIH Funding Opportunity Announcement supports a single Coordinating Center and Data Management Group (CDMG) through a U01 cooperative agreement. The CDMG is intended to function as the operational backbone for a larger research Consortium focused on cancers found through screening.
2) What is the main goal of the larger Consortium that the CDMG will support?
The Consortium goal is to perform deep molecular and cellular characterization of screen-detected early lesions and compare them with (1) cancers detected in the interval between screenings (interval cancers) and (2) cancers detected after symptoms appear. The comparisons are intended to help clarify why some early lesions remain indolent while others become aggressive, and to improve prediction of which lesions are likely to progress.
3) Why is NIH focusing on screen-detected lesions in this program?
The scientific motivation described in the announcement is that screening can detect abnormalities that may never become clinically dangerous as well as lesions that represent truly early forms of lethal disease. The program is structured to help distinguish the biological features associated with lesions found by screening from those associated with faster-growing or symptomatic cancers.
4) Is this FOA for individual cancer biology research projects at specific sites?
No. This FOA is explicitly for the centralized Coordinating Center and Data Management Group that coordinates collaboration and makes the data and biospecimen infrastructure work across the Consortium. The independent, site-focused multidisciplinary biology projects are part of the broader Consortium but are not what this specific FOA is soliciting.
5) What cancer sites are expected to be represented by the Consortium research teams?
The announcement indicates that individual research teams in the Consortium are expected to study one or more of the following cancer sites: breast, prostate, lung, melanoma, and pancreas.
6) What kinds of comparisons are central to the Consortium’s scientific approach?
The Consortium is designed to compare screen-detected early lesions with interval cancers (those found between screening rounds) and with cancers detected after symptoms appear. By contrasting these groups, the program aims to identify molecular and cellular features that correlate with indolent versus aggressive behavior and to improve predictions about lesion fate over time.
7) What kinds of biological information does the program emphasize?
The description emphasizes work spanning tumor tissue, individual cancer and noncancer cells, and key elements of the tumor microenvironment. It highlights approaches that can capture both molecular states and cellular composition, and it encourages enabling technologies and analytical strategies to define phenotypes of early lesions and support predictive understanding of lesion behavior.
8) What is a major shared deliverable across the Consortium?
A major shared deliverable is an annotated biospecimen repository that includes screen-detected lesions and interval cancers, along with associated clinical and other metadata needed to interpret molecular findings.
9) What role does the CDMG play in the biospecimen repository?
The CDMG is described as central to making the repository usable and scientifically credible by establishing consistent protocols, data standards, and tracking systems. This includes developing and maintaining data management systems, supporting protocol development for the biorepository, and ensuring specimens and data are annotated to support cross-study comparisons and integrative analyses.
10) What are the three main responsibility areas for the CDMG?
The responsibilities are spelled out in three main areas:
- Consortium coordination: Supporting consortium-wide meetings, conferences, and collaborative activities (such as scheduling, agenda development, tracking action items, and maintaining communication among investigators and NIH staff).
- Statistical and computational support: Supporting study design considerations, analysis plans, cross-team harmonization, and integrative computational analyses that enable combination and comparison of data across teams.
- Data management and biorepository protocol development: Leading data dictionaries, quality control processes, governance for data submissions and access within the Consortium, and the practical mechanics needed to keep a multi-site repository consistent over time.
11) What does it mean that the award mechanism is a U01 cooperative agreement?
The opportunity uses a U01 cooperative agreement mechanism, which signals substantial NIH involvement in the project’s oversight and coordination compared with a standard research grant.
12) How many awards were expected under this FOA?
The funding details state that one award was expected.
13) What funding level is described for this opportunity?
The announcement lists an estimated total program funding level of $500,000 and an award ceiling of $300,000.
14) Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
15) When was the FOA posted and what were the closing dates?
The FOA was posted on June 6, 2014. The original and current closing date is listed as September 17, 2014. The archive date is October 18, 2014.
16) Is this opportunity currently open for applications?
Based on the listed closing date (September 17, 2014) and archive date (October 18, 2014), the opportunity appears to be historical rather than currently open.
17) Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (including small businesses and other than small businesses), and state governments. The opportunity also lists additional categories such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and eligible federal agencies.
18) Are foreign (non-U.S.) institutions eligible to apply?
No. Foreign institutions and other non-U.S. entities are not eligible to apply.
19) Are non-U.S. components of U.S. organizations eligible?
No. The announcement states that non-U.S. components of U.S. organizations are not eligible.
20) Are foreign components allowed under this program?
Yes. The announcement indicates that foreign components (as defined by NIH policy) are allowed, which typically refers to specific project elements conducted abroad under an otherwise eligible applicant organization, subject to NIH rules.
21) What NIH agency and general program areas are associated with this FOA?
The participating agency is the National Institutes of Health (NIH). The program is aligned to cancer cause and prevention research, cancer detection and diagnosis research, and cancer biology research. The CFDA numbers listed are 93.393, 93.394, and 93.396.
22) What is the practical purpose of funding a single CDMG for the Consortium?
The CDMG award is intended to ensure the Consortium functions as a unified program rather than a loose federation of projects. By centralizing coordination, analytics support, and data/biorepository infrastructure, NIH aims to make datasets and specimens comparable across tumor types and teams, accelerate shared discovery, and support stronger conclusions than isolated studies could produce.
Browse more opportunities from the same category: Education Health
Next opportunity: Molecular and Cellular Characterization of Screen Detected Lesions (U01)
Previous opportunity: Office of Postsecondary Education (OPE) Language Resource Centers Program CFDA Number 84.229A
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 14 011
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 14 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| Molecular and Cellular Characterization of Screen Detected Lesions (U01) Apply for RFA CA 14 010 Funding Number: RFA CA 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovation Corps (I Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp) Apply for PAR 14 261 Funding Number: PAR 14 261 Agency: National Institutes of Health Category: Education Health Funding Amount: $25,000 |
| Outstanding Investigator Award (R35) Apply for PAR 14 267 Funding Number: PAR 14 267 Agency: National Institutes of Health Category: Education Health Funding Amount: $600,000 |
| The National Drug Abuse Treatment Clinical Trials Network (UG1) Apply for RFA DA 15 008 Funding Number: RFA DA 15 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Connectomes Related to Human Disease (U01) Apply for PAR 14 281 Funding Number: PAR 14 281 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 011 Funding Number: RFA DA 15 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Extracellular Vesicles in HIV/AIDS and Substance Abuse (R21) Apply for RFA DA 15 012 Funding Number: RFA DA 15 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,000,000 |
| Innovative Research in Cancer Nanotechnology (IRCN) (U01) Apply for PAR 14 285 Funding Number: PAR 14 285 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Centers of Cancer Nanotechnology Excellence (CCNEs) (U54) Apply for RFA CA 14 013 Funding Number: RFA CA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College Attending Youth (U01) Apply for RFA DA 15 010 Funding Number: RFA DA 15 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Arts Based Approaches in Palliative Care for Symptom Management (R01) Apply for PAR 14 294 Funding Number: PAR 14 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01) Apply for RFA CA 14 012 Funding Number: RFA CA 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| New Approaches to Synthetic Lethality for Mutant KRas Dependent Cancers (U01) Apply for PAR 14 314 Funding Number: PAR 14 314 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Obesity and Asthma Awareness and Self Management (R01) Apply for PA 14 316 Funding Number: PA 14 316 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition AIDS Malignancy Clinical Trials Consortium (UM1) Apply for RFA CA 14 502 Funding Number: RFA CA 14 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $21,400,000 |
| Developing Interventions for Health Enhancing Physical Activity (R21/R33) Apply for PAR 14 321 Funding Number: PAR 14 321 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Training Modules to Enhance Data Reproducibility (R25) Apply for RFA GM 15 006 Funding Number: RFA GM 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Limited Competition International Agency for Research on Cancer (IARC) Monographs Program (U01) Apply for RFA CA 14 503 Funding Number: RFA CA 14 503 Agency: National Institutes of Health Category: Education Health Funding Amount: $859,000 |
| Advancing Interventions to Improve Medication Adherence (R21) Apply for PA 14 335 Funding Number: PA 14 335 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 14 339 Funding Number: PAR 14 339 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 14 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.